DaVita Inc. $DVA Stock Sold by Candriam S.C.A.

Key Points

• Candriam S.C.A. cut its DaVita stake by 14.6% in the third quarter, selling 8,378 shares. It retained 48,885 shares, valued at about $8.6 million.
• Institutional investors own 90.12% of DaVita; Berkshire Hathaway and several other large institutions reported new stakes in the second quarter.
• DaVita beat quarterly expectations, reporting earnings of $3.82 per share and revenue of $3.58 billion, with revenue up 4.6% year over year. Analysts’ consensus rating was “Moderate Buy,” with an average price target of $235.86.

Candriam S.C.A. reduced its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 14.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 48,885 shares of the company's stock after selling 8,378 shares during the quarter. Candriam S.C.A. owned approximately 0.08% of DaVita worth $8,582,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Berkshire Hathaway Inc bought a new stake in DaVita in the 2nd quarter valued at $6,425,269,000. BlackRock Inc. bought a new position in DaVita during the second quarter worth $547,520,000. Bank of America Corp DE bought a new position in DaVita during the second quarter worth $145,057,000. Bank of New York Mellon Corp bought a new position in DaVita during the second quarter worth $101,127,000. Finally, Deutsche Bank AG acquired a new position in shares of DaVita in the second quarter valued at $46,356,000. 90.12% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on DVA. Truist Financial dropped their price objective on shares of DaVita from $250.00 to $215.00 and set a "hold" rating on the stock in a research report on Friday, August 7th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $265.00 target price on shares of DaVita in a report on Wednesday, August 5th. Raymond James Financial set a $220.00 price target on shares of DaVita in a research note on Friday, August 7th. Oppenheimer set a $220.00 price target on shares of DaVita in a research note on Friday, August 7th. Finally, Wall Street Zen cut shares of DaVita from a "buy" rating to a "hold" rating in a report on Saturday, October 31st. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $235.86.

DaVita Price Performance

DVA opened at $185.51 on Tuesday. The business has a fifty day simple moving average of $182.61 and a 200 day simple moving average of $179.01. The company has a market capitalization of $11.67 billion, a PE ratio of 13.66, a price-to-earnings-growth ratio of 0.49 and a beta of 0.87. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $247.49.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The company reported $3.82 EPS for the quarter, beating analysts' consensus estimates of $3.57 by $0.25. The firm had revenue of $3.58 billion for the quarter, compared to analyst estimates of $3.52 billion. DaVita had a negative return on equity of 225.93% and a net margin of 6.49%. The company's revenue for the quarter was up 4.6% on a year-over-year basis. During the same period in the prior year, the firm posted $2.51 EPS. Equities analysts anticipate that DaVita Inc. will post 14.66 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc is a healthcare provider focused on kidney care. Its core business is operating outpatient dialysis centers that provide treatment and related services to people with chronic kidney failure.

The company also offers home dialysis programs, provides dialysis services to patients in hospitals, and supports kidney care through services such as care coordination and education. DaVita primarily serves patients in the United States and also operates in international markets.

Founded in 1994 as Total Renal Care, the company adopted the name DaVita in 2000.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.